MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) — Market Cap & Net Worth
Market Cap & Net Worth: MBX Biosciences, Inc. Common Stock (MBX)
MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) has a market capitalization of $1.76 Billion ($1.76 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6644 globally and #2081 in its home market, demonstrating a -2.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MBX Biosciences, Inc. Common Stock's stock price $61.57 by its total outstanding shares 47597536 (47.60 Million). Also see balance sheet size of MBX Biosciences, Inc. Common Stock for a full breakdown of the balance sheet.
MBX Biosciences, Inc. Common Stock Market Cap History: 2024 to 2026
MBX Biosciences, Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows growth from $877.22 Million to $2.93 Billion (95.45% CAGR). Also see MBX cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
MBX Biosciences, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.07% | #191 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #747 of 3165 |
Weight: MBX Biosciences, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MBX Biosciences, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MBX Biosciences, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MBX Biosciences, Inc. Common Stock (MBX) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MBX by Market Capitalization
Companies near MBX Biosciences, Inc. Common Stock in the global market cap rankings as of September 18, 2026. Review MBX Biosciences, Inc. Common Stock (MBX) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to MBX Biosciences, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
MBX Biosciences, Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, MBX Biosciences, Inc. Common Stock's market cap moved from $877.22 Million to $ 2.93 Billion, with a yearly change of 95.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.93 Billion | +95.21% |
| 2025 | $1.50 Billion | +71.13% |
| 2024 | $877.22 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of MBX Biosciences, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.76 Billion USD |
| MoneyControl | $1.76 Billion USD |
| MarketWatch | $1.76 Billion USD |
| marketcap.company | $1.76 Billion USD |
| Reuters | $1.76 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more